Lactiga is a biotherapeutics company developing a novel inhaled biologic comprising pooled human milk IgA antibodies as a replacement therapy for patients with mucosal IgA antibody deficiencies including common variable immune deficiency (CVID, a rare disease) and selective IgA deficiency (SIgAD). The company seeks to advance its lead asset, LCTG-001, to a Phase II clinical trial to position it for a substantial exit to a larger pharma company.